|
The Bank Vontobel Group The Vontobel Group offers superior financial services to clients around the world based on Swiss private banking traditions. It is focused on three business areas: Private Banking, Investment Banking and Institutional Asset Management & Investment Funds. The Vontobel Group is one of Switzerland’s leading asset managers for both private and institutional clients. The focus in Investment Banking is on brokerage, derivative products, securities and forex trading as well as corporate finance.We are one of the largest brokers on the Swiss market for stocks, especially Swiss small and mid caps. Our award-winning Vontobel Research has distinguished itself by the high degree of accuracy of its earnings estimates.Vontobel is among the “Top 3” in Switzerland in the issue of derivative and structured products. Our Corporate Finance team advises companies, especially in the German-speaking region, in matters relating to capital market financing and Mergers & Acquisitions. In the past, Bank Vontobel has lead managed the listing in Switzerland and Germany of a number of companies, some of them Austrian. Vontobel Group has branch offices located in Zurich, Geneva, Cologne, Frankfurt, Salzburg, Vienna and New York. Vontobel Holding AG registered shares have been listed on the Swiss Exchange since 1986. Stock market capitalization at the end of December 2003 amounted to CHF 1.68 bn. A key element of the Group’s identity is its independence.The Vontobel family, the Vontobel Foundation and management own a majority of the share capital and voting rights. This ownership structure makes Vontobel one of the few truly independent banking groups in Switzerland. |
 |
| BioExec
Ventures BioExec Ventures, LLC is a unique partnership of industry-experienced executives devoted to the biotechnology sector and its future growth and prosperity. We provide business development services, US representation for international firms and interim executive management to biotechnology and pharmaceutical companies, with an emphasis on U.S. representation for international biotechnology firms. Our mission is to accelerate value creation for tomorrow's industry-leading products and companies through timely, world-class industry and management expertise. We have amassed a significant number of executive-level contacts in premier pharmaceutical and biotech companies as well as in investment banking, venture capital, consulting and other industry-support sectors. Penetrating the US market and building partnerships is a critical step in the growth trajectories of innovative life-science and biotech start-ups in Europe and across the globe. BioExec Ventures leverages this extensive contact list to provide executive-level services to international BioPharma firms that lack these connections in the US, or cannot afford the time that it takes to build them. As part of your team, we can provide complete US business development activities and interim management at a fraction of the cost for a full-time employee, and our broad network amplifies the investment. |
 |
| Gilde
Investment Management Fund profile Focus areas include biopharmaceuticals, diagnostics and medical devices. Gilde typically acts as (co-)lead investor in international
consortia, preferably in seed and first round and in exceptional
cases in second and mezzanine rounds. Investments range from €
500,000 - € 8 million depending on the development stage of
the company. Portfolio companies Contact: Marc Perret, Director |
|
| Global
Life Science Ventures Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV supports early-stage groups originating from universities, scientific institutions or industry, but will also invest in selected later-stage companies, including buyouts. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds greater than EUR 200 million. With three locations in Germany, Switzerland and the United Kingdom, GLSV acts as one team with a global perspective. An industry-born team. GLSV has established a strong investment team and a network of advisors with many years of complementary experience in the life science industry. The expertise of the partners ranges from industrial experience in molecular biology, immunology, diagnostics and medical devices to marketing, senior level strategic business development, finance and administration. Track record. Over the years, GLSV has achieved a sound track record through discerning investments in high-potential companies. After registration of the original fund in 1996, the available capital of Euro 66 million (excluding limited funds reserved for follow-on investments) has been invested in a portfolio of 18 ventures active in the life sciences. The positive development of the first fund has been highlighted by successful IPOs and merger & acquisition transactions and also included a number of board seat representations, several of which were at chairman level. Pro-active syndicate partner. GLSV offers its investees access to the capital, experience and networks of a group of international venture capitalists that invest in the life sciences on a global scale. Syndicate partnerships are made with funds whose investment criteria and philosophy match those of GLSV. A global perspective is provided by syndicate partnerships with leading US-based funds. The GLSV portfolio includes companies active in many areas of the life sciences ranging from biopharmaceuticals, cancer, immunology, vaccines and genomics to diagnostics, medical devices and healthcare services. GLSV II. In 2002, GLSV announced the successful completion of the financing of its second fund. The new fund of Euro 143 million met the projected target by more than doubling the size of its predecessor. All existing investors renewed their financial commitment to the fund. The second fund has so far been invested in 11 companies several of which appear ready for an exit in the short to medium term. |
|
Katan
Associates Katan is a globally based advisory services organization that provides a variety of integrated and interdisciplinary business and financial services to developing, knowledge-based growth and biotechnology companies. Our clients will share in the diversified operational, financial and strategic experiences that Katan’s senior management has gained in their various roles with numerous companies. We have a proven track record of adding significant value to formative-stage companies, providing management, financial, business development and strategic basis for a company’s growth and success. Katan assists in any of the following areas: |
 |
Morgan
Lewis Morgan, Lewis & Bockius LLP (“Morgan Lewis”) is a leading international law firm with 16 offices worldwide: Frankfurt am Main, London, Brussels, New York, Washington, Philadelphia, Los Angeles, San Francisco, Miami, Northern Virginia, Harrisburg, Pittsburgh, Princeton, Palo Alto, Irvine and Tokyo. Founded 1873 in Philadelphia, the firm comprises nearly 1,300 lawyers, practicing in all essential areas of commercial law, including corporate law, financial markets law and tax law. Opened in 1989, the Frankfurt office is a highly specialized office concentrating on corporate (in particular, takeovers and M&A), securities services, and IP/technology, as well as German and European antitrust law. Lawyers are qualified in the German and other international jurisdictions (in particular in U.S. law) and are able and accustomed to handling complex cross-border assignments The Frankfurt office is specialized in the following areas:
|
 |
| Nomura
International Nomura Phase4 Ventures ("NPV") is a division of London based Nomura International plc, part of The Nomura Group. Established in 2004, NPV has evolved from Nomura's BioPharma Private Equity Group which has been operating since 1998. NPV invests in private companies in the US and Europe in the emerging healthcare space (biopharma, speciality pharmaceuticals and medical devices) through the fund Nomura Phase4 Ventures LP. The group works with a number of senior advisors with extensive operating experience in pharmaceutical and biotechnology companies. |
|
|
Novartis AG, a holding company organized under Swiss law, owns directly or indirectly all Novartis companies worldwide. The Novartis Group is divided into two divisions: Pharmaceuticals and Consumer Health. The Pharmaceuticals Division is organized into five business units: Primary Care, Oncology, Transplantation, Mature Products, and Optalmics. The six business units of the Consumer Health Division are: Generics, Over-the-Counter self medication (OTC), Animal Health, Medical Nutrition, Infant & Baby, and CIBA Vision. The Novartis Pharamaceuticals Division is a world leader in discovery, development, manufacture, and marketing of prescription medicines. Its goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around the world. This goal is supported by a dedicated organization operating in more than 140 countries through approximately 80 affiliates. |
|
SWX
Swiss Exchange The SWX Swiss Exchange ranks among the world’s most technologically advanced securities exchanges. Backed by the strength of Switzerland’s financial marketplace, it resolutely pursues an internationally oriented strategy. In transnational collaboration with partner organisations, the SWX Swiss Exchange provides first-rate securities exchange services to all parties involved. Not only is its broad product palette a convincing factor in this regard, but also its fully integrated and totally automated trading, clearing and settlement system that remains unique in the world. The SWX Swiss Exchange offers innovative, international companies access to the Swiss capital market. A public placement of securities in one of its trading segments affords companies a high degree of global visibility among investors. An initial public offering in Switzerland is an attractive opportunity for companies to raise equity capital, especially those in the life science, IT and micro- and nanotechnology industries. SWX Swiss Exchange |
|
Techno
Venture Management Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany, and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth. TVM funds have made investments in 200 technology companies in Europe and the United States. A pivotal objective is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic. |
|
